NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications
August 09, 2016 05:00 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, August 9, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that
research results from the NVP015 program...
NeuroVives nya strategi för behandling av mitokondriell sjukdom publicerad i Nature Communications
August 09, 2016 05:00 ET
|
NeuroVive Pharmaceutical AB
Lund den 9 augusti 2016 - NeuroVive Pharmaceutical AB
(Nasdaq Stockholm: NVP, OTCQX:NEVPF), ett
företag inom mitokondriell medicin, meddelar idag att resultat från
forskningsprogrammet NVP015 kring en...
NeuroVive informerar om Arbutus Biopharmas uppsägning av licensavtalet
July 06, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Lund den 6 juli, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP,
OTCQX: NEVPF), meddelar idag att de, från Arbutus Biopharma (tidigare OnCore
Biopharma, Inc.), mottagit en av NeuroVive...
NeuroVive announces Arbutus Biopharma’s notice of termination
July 06, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, July 6, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP,
OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus
Biopharma (formerly OnCore Biopharma,...
NeuroVive announces CiPRICS study completes enrolment
June 07, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
Lund, Sweden, 7 June 2016 – NeuroVive Pharmaceutical AB (publ), announces that
the CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) clinical
research team at the Department of...
NeuroVive meddelar att CiPRICS-studien är fullrekryterad
June 07, 2016 02:30 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ) meddelar att det kliniska forskarteamet på
Thoraxkliniken vid Skånes universitetssjukhus i Lund har rekryterat samtliga 150
patienter i CiPRICS-studien (Ciclosporin...
NeuroVives aktie uppgraderas till OTC Markets Group – OTCQX Best Market i USA
June 02, 2016 07:00 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ), läkemedelsbolaget inom mitokondriell
medicin, meddelar att bolagets aktie i USA har uppgraderats till OTC Markets
Groups best market OTCQX. Uppgraderingen innebär...
NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US
June 02, 2016 07:00 ET
|
NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has
announced that the company’s share has been upgraded to trading on the OTC
Market Group’s best market, OTCQX in the US. The...
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
May 31, 2016 02:46 ET
|
NeuroVive Pharmaceutical AB
Med hänvisning till 4 kap. 9 § lagen (1991:980) om handel med finansiella
instrument meddelas härmed att till följd av genomförd nyemission i NeuroVive
Pharmaceutical AB (publ) (”NeuroVive”) beslutad...
NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes
May 31, 2016 02:46 ET
|
NeuroVive Pharmaceutical AB
Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act
(1991:980), the company is hereby reporting that as a result of new share issue
conducted by NeuroVive Pharmaceutical AB...